In a word, pharmacological targeting of SIRT6 will be an innovative therapeutic strategy for hypertension patients in future.286 Tubastatin A (TubA), a highly selective HDAC6 inhibitor, can significantly improve Ang-II-induced vasoconstriction and elevate blood pressure by inhibiting the expression and activity of Ang-II-induced HDAC6 and reducing the degradation of CSEγ. This evidence concerns the gene HDAC6 and Hypertension.